Telik Inc. About
Telik Inc. Telik, Inc. (Nasdaq: TELK) of Palo Alto, CA is a biopharmaceutical
company dedicated to discovering, developing and commercializing novel small molecule
drugs to treat cancer and other serious diseases. The Company discovered
all of its product candidates using its proprietary technology, Target-Related
Affinity Profiling (TRAP). Their most advanced product is TELCYTA™ (TLK286),
a novel cancer cell-activated chemotherapeutic currently in three Phase
3 registration trials in advanced ovarian cancer and non-small cell lung cancer.
A second development candidate, TELINTRA™ (TLK199), is in a Phase 2 clinical
trial in myelodysplastic syndrome and may also have utility in the treatment
of chemotherapy-induced cytopenia. TELCYTA --advanced ovarian
cancer and non-small cell lung
cancer TELINTRA myelodysplastic
syndrome More About Telik